IMNM
IMNM clinical trials: Immunome Inc.
Every trial on ClinicalTrials.gov where Immunome Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 11
- Trials linked
- 11
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
IMNM on the catalyst calendar · IMNM registry changes
- Primary completion Jan 2029Sponsor estimatePhase 1NCT07578571A Phase 1 Study of IM-1617 in Participants With Advanced CancerImmunome, Inc. · Colorectal CancerRecruitingIMNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2027Sponsor estimatePhase 1NCT07610005A Relative Bioavailability and Bioequivalence Study of Varegacestat in Healthy ParticipantsImmunome, Inc. · HealthyRecruitingIMNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 2030Sponsor estimatePhase 1NCT07890246A Phase 1 Study of IM-1340 in Participants With Advanced CancerImmunome, Inc. · Colorectal CancerNot yet recruitingIMNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2029Sponsor estimatePhase 1NCT07505771A Phase 1 Study of 177Lu-IM-3050 in Participants With Advanced CancerImmunome, Inc. · Solid MalignanciesRecruitingIMNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion May 2028Sponsor estimatePhase 1NCT06823167A Phase 1 Study of IM-1021 in Participants With Advanced CancerImmunome, Inc. · Solid MalignanciesRecruitingIMNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 3, 2025ActualPhase 2/Phase 3NCT04871282A Study of AL102 in Patients With Progressing Desmoid TumorsImmunome, Inc. · DesmoidActive, not recruitingIMNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 5, 2025ActualPhase 1NCT06841315A Varegacestat Hepatic Impairment StudyImmunome, Inc. · Healthy VolunteerCompletedIMNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Mar 11, 2025ActualPhase 1NCT06845852A Phase 1 Mass Balance Study of VaregacestatImmunome, Inc. · Healthy VolunteerCompletedIMNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 8, 2025ActualPhase 1NCT06855264A Cardiac Liability Study of Varegacestat in Healthy ParticipantsImmunome, Inc. · Healthy VolunteerCompletedIMNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 30, 2024ActualPhase 1NCT06677996A Phase 1 Study to Examine the Effects of Itraconazole After Single Dose Administration of Varegacestat (AL102) to Healthy ParticipantsImmunome, Inc. · Healthy VolunteerCompletedIMNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 6, 2023ActualPhase 1NCT05429021IMM-BCP-01 in Mild to Moderate COVID-19Immunome, Inc. · SARS-CoV2 InfectionTerminatedIMNMLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 11 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner